Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cardiovascular Diabetology
Published in: Cardiovascular Diabetology 1/2015

Open Access 01-12-2015 | Original investigation

Polymorphisms of the Peroxisome Proliferator-Activated Receptor-γ (rs1801282) and its coactivator-1 (rs8192673) are associated with obesity indexes in subjects with type 2 diabetes mellitus

Authors: Peter Kruzliak, Andreana P Haley, Jovana Nikolajevic Starcevic, Ludovit Gaspar, Daniel Petrovic

Published in: Cardiovascular Diabetology | Issue 1/2015

Login to get access

Abstract

ᅟ

The aim of this study was to clarify whether common single nucleotide polymorphisms (SNPs) of the Peroxisome Proliferator-Activated Receptor-γ (PPAR-γ) gene (rs1801282) and the Peroxisome Proliferator-Activated Receptor-γ Coactivator-1 (PGC-1α) gene (rs8192673) are associated with obesity indexes (BMI, waist circumference) in subjects with type 2 diabetes mellitus (T2DM) in Caucasian population. The second aim was to find an association of both polymorphisms with T2DM.

Methods

Two exonic SNPs of both genes rs1801282 of the PPAR-γ gene and rs8192673 of the PGC-1α gene) were genotyped in 881 unrelated Slovene subjects (Caucasians) with T2DM and in 348 subjects without T2DM (control subjects).

Results

Female homozygotes with the CC genotype of the rs8192673 had higher waist circumference in comparison with subjects with other genotypes. Homozygotes (females, males) with wild allele (Pro) of the rs1801282 (Pro12Ala polymorphism) had higher waist circumference in comparison with subjects with other genotypes. In the study, there were no differences in the distributions of the rs8192673 and the rs1801282 genotypes between patients with T2DM and controls. Linear regression analyses for both polymorphisms were performed and demonstrated an independent effect of the rs1801282 of the PPAR-γ on waist circumference in subjects with T2DM, whereas an independent effect on waist circumference was not demonstrated for the rs8192673 of the PGC-1α gene.

Conclusions

In a large sample of the Caucasians the rs8192673 of the PGC-1α gene and the rs1801282 of the PPAR-γ gene were associated with waist circumference in subjects with T2DM.
Literature
1.
2.
Du Y, Heidemann C, Gößwald A, Schmich P, Scheidt-Nave C. Prevalence and comorbidity of diabetes mellitus among non-institutionalized older adults in Germany - results of the national telephone health interview survey 'German Health Update (GEDA)' 2009. BMC Public Health. 2013;13:166.CrossRefPubMedCentralPubMed
3.
Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87:4–14.CrossRefPubMed
4.
Whiting DR, Guariguata L, Weil C, Shaw J. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract. 2011;94:311–21.CrossRefPubMed
5.
Shigemizu D, Abe T, Morizono T, Johnson TA, Boroevich KA, Hirakawa Y, et al. The Construction of Risk Prediction Models Using GWAS Data and Its Application to a Type 2 Diabetes Prospective Cohort. PLoS One. 2014;9(3):e92549.CrossRefPubMedCentralPubMed
6.
7.
Klemenc-Ketis Z, Peterlin B. Family history as a predictor for disease risk in healthy individuals: a cross-sectional study in Slovenia. PLoS One. 2013;8(11), e80333.CrossRefPubMedCentralPubMed
8.
9.
Petrovic MG, Kunej T, Peterlin B, Dovc P, Petrovic D. Gly482Ser polymorphism of the peroxisome proliferator-activated receptor-gamma coactivator-1 gene might be a risk factor for diabetic retinopathy in Slovene population (Caucasians) with type 2 diabetes and the Pro12Ala polymorphism of the PPARgamma gene is not. Diabetes Metab Res Rev. 2005;21(5):470–4.CrossRefPubMed
10.
Maver A, Hristovski D, Rindflesch TC, Peterlin B. Integration of data from omic studies with the literature-based discovery towards identification of novel treatments for neovascularization in diabetic retinopathy. Biomed Res Int. 2013;2013:848952.CrossRefPubMedCentralPubMed
11.
Soyal S, Krempler F, Oberkofler H, Patsch W. PGC-1alpha: a potent transcriptional cofactor involved in the pathogenesis of type 2 diabetes. Diabetologia. 2006;49(7):1477–88.CrossRefPubMed
12.
Habek JC, Lakusic N, Kruzliak P, Sikic J, Mahovic D, Vrbanic L. Left ventricular diastolic function in diabetes mellitus type 2 patients: correlation with heart rate and its variability. Acta Diabetol. 2014;51:999–1005.CrossRefPubMed
13.
Sharma S, Saxena S, Srivastav K, Shukla R, Mishra N, Meyer CH, et al. Nitric oxide and oxidative stress is associated with severity of diabetic retinopathy and retinal structural alterations. Clin Experiment Ophthalmol. 2015. doi:10.​1111/​ceo.​12506.
14.
Bendzala M, Kruzliak P, Gaspar L, Soucek M, Mrdovic I, Sabaka P, et al. Prognostic significance of dipping in older hypertensive patients. Blood Press. 2015;24:103–10.CrossRefPubMed
15.
O’Rahilly S, Barroso I, Wareham NJ. Genetic factors in type 2 diabetes: the end of the beginning? Science. 2005;307:370–3.CrossRefPubMed
16.
Barroso I, Luan J, Middelberg RP, Harding AH, Franks PW, Jakes RW, et al. Candidate gene association study in type 2 diabetes indicates a role for genes involved in β-cell function as well as insulin action. PLoS Biol. 2003;1:41–55.CrossRef
17.
Pratley RE, Thompson DB, Prochazka M, Baier L, Mott D, Ravussin E, et al. An autosomal genomic scan for loci linked to prediabetic phenotypes in Pima Indians. J Clin Invest. 1998;101:1757–64.CrossRefPubMedCentralPubMed
18.
Ek J, Andersen G, Urhammer SA, Gaede PH, Drivsholm T, Borch-Johnsen K, et al. Mutation analysis of peroxisome proliferator-activated receptor-gamma coactivator-1 (PGC-1) and relationships of identified amino acid polymorphisms to Type II diabetes mellitus. Diabetologia. 2001;44(12):2220–6.CrossRefPubMed
19.
Andersen G, Hansen T, Gharani N, Frayling TM, Owen KR, Sampson M, et al. A common Gly482Sser polymorphism of PGC-1 is associated with type 2 diabetes mellitus in two European populatins (Abstract). Diabetes. 2002;51 suppl 2:A49.
20.
Lacquemant C, Chikri M, Boutin P, Samson C, Froguel P. No association between the G482S polymorphism of the proliferator-activated receptor-γ coactivator-1 gene and Type II diabetes in French Caucasias. Diabetologia. 2002;45:602–3.CrossRefPubMed
21.
Hara K, Tobe K, Okada T, Kadowaki H, Akanuma Y, Ito C, et al. A genetic variation in the PGC-1 gene could confer insulin resistance and susceptibility to Type II diabetes. Diabetologia. 2002;45:740–3.CrossRefPubMed
22.
Muller YL, Bogardus C, Beamer BA, Shuldiner AR, Baier LJ. A functional variant in the peroxisome proliferator-activated receptor gamma2 promoter is associated with predictors of obesity and type 2 diabetes in Pima Indians. Diabetes. 2003;52(7):1864–71.CrossRefPubMed
23.
Muller YL, Bogardus C, Pedersen O, Baier L. A Gly482Ser missense mutation in the peroxisome proliferator-activated receptor-γ coactivator-1 is associated with altered lipid oxidation and early insulin secretion in Pima Indians. Diabetes. 2003;52:895–8.CrossRefPubMed
24.
Esterbauer H, Oberkofler H, Linnemayr V, Iglseder B, Hedegger M, Wolfsgruber P, et al. Peroxisome proliferator-activated receptor-gamma coactivator-1 gene locus: associations with obesity indices in middle-aged women. Diabetes. 2002;51(4):1281–6.CrossRefPubMed
25.
26.
Janssen I, Katzmarzyk PT, Ross R. Waist circumference and not body mass index explains obesity-related health risk. Am J Clin Nutr. 2004;79(3):379–84.PubMed
27.
Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G. et al; European Society of Hypertension; European Society of Cardiology. 2007 ESH-ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Blood Press. 2007;16:135–232.CrossRef
28.
Kunej T, Globocnik Petrovic M, Dovc P, Peterlin B, Petrovic D. A Gly482Ser polymorphism of the peroxisome proliferator-activated receptor-gamma coactivator-1 (PGC-1) gene is associated with type 2 diabetes in Caucasians. Folia Biol (Praha). 2004;50(5):157–8.
29.
Meshkani R, Taghikhani M, Larijani B, Bahrami Y, Khatami S, Khoshbin E, et al. Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-gamma2 (PPARgamma-2) gene is associated with greater insulin sensitivity and decreased risk of type 2 diabetes in an Iranian population. Clin Chem Lab Med. 2007;45(4):477–82.CrossRefPubMed
30.
31.
32.
Marcadenti A, Fuchs FD, Matte U, Sperb F, Moreira LB, Fuchs SC. Effects of FTO RS9939906 and MC4R RS17782313 on obesity, type 2 diabetes mellitus and blood pressure in patients with hypertension. Cardiovasc Diabetol. 2013;12:103.CrossRefPubMedCentralPubMed
33.
34.
Gu Q, Yazdanpanah M, van Hoek M, Hofman A, Gao X, de Rooij FW, et al. Common variants in PCSK1 influence blood pressure and body mass index. J Hum Hypertens. 2015;29(2):82–6.CrossRefPubMed
35.
Corella D, Sorlí JV, González JI, Ortega C, Fitó M, Bulló M, et al. Novel association of the obesity risk-allele near Fas Apoptotic Inhibitory Molecule 2 (FAIM2) gene with heart rate and study of its effects on myocardial infarction in diabetic participants of the PREDIMED trial. Cardiovasc Diabetol. 2014;13:5.CrossRefPubMedCentralPubMed
36.
Ghanbari M, Sedaghat S, de Looper HW, Hofman A, Erkeland SJ, Franco OH, et al. The association of common polymorphisms in miR-196a2 with waist to hip ratio and miR-1908 with serum lipid and glucose. Obesity (Silver Spring). 2015;23(2):495–503.CrossRef
37.
Frayling TM, Timpson NJ, Weedon MN, Zeggini E, Freathy RM, Lindgren CM, et al. A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science. 2007;316:889–93.CrossRefPubMedCentralPubMed
38.
Vaisse C, Clement K, Guy-Grand B, Froguel P. A frameshift mutation in MC4R is associated with a dominant form of obesity. Nature Genet. 1998;20:113–4.CrossRefPubMed
39.
Thomas MKYK, Tenser MS, Wong GG, Habener JF. Bridge-1, a novel PDZ- domain coactivator of E2A-mediated regulation of insulin gene transcription. Mol Cell Biol. 1999;19:8492.PubMedCentralPubMed
40.
Volinic JL, Lee JH, Eto K, Kaur V, Thomas MK. Overexpression of the coactivator bridge-1 results in insulin deficiency and diabetes. Mol Endocrinol. 2006;20:167.CrossRefPubMed
Metadata
Title
Polymorphisms of the Peroxisome Proliferator-Activated Receptor-γ (rs1801282) and its coactivator-1 (rs8192673) are associated with obesity indexes in subjects with type 2 diabetes mellitus
Authors
Peter Kruzliak
Andreana P Haley
Jovana Nikolajevic Starcevic
Ludovit Gaspar
Daniel Petrovic
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2015
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/s12933-015-0197-0

Other articles of this Issue 1/2015

Cardiovascular Diabetology 1/2015 Go to the issue

Original investigation

Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study

Original investigation

The receptor for advanced glycation end products and risk of peripheral arterial disease, amputation or death in type 2 diabetes: a population-based cohort study

Original investigation

Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events

Original investigation

Effect of the glucagon-like peptide-1 analogue liraglutide on coronary microvascular function in patients with type 2 diabetes – a randomized, single-blinded, cross-over pilot study

Original investigation

Enhancement of insulin-mediated rat muscle glucose uptake and microvascular perfusion by 5-aminoimidazole-4-carboxamide-1-β-d-ribofuranoside

Original investigation

High-risk type-2 diabetes mellitus patients, without prior ischemic events, have normal blood platelet functionality profiles: a cross-sectional study
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits